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Abstract 
Colorectal carcinomas are among the most common tumor types and are generally treated 
with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 
46-year-old patient with metastatic rectal carcinoma who received second-line therapy with 
irinotecan and developed isolated transient dysarthria (with normal MR imaging of the 
brain) following each administration of irinotecan. Neurological and logopedical evaluation 
revealed that the dysarthria predominantly resulted from a reduced capacity in fine-tuning 
of motor functions of the tip of the tongue and a minimal reduction in the power of speech 
at labiodental contact. As hypoglossal nerve activity has been reported to be especially 
susceptible to cholinergic stimulation and irinotecan can cause cholinergic side effects by 
binding to and inactivating acetylcholinesterase, we suspect this mechanism to be 
responsible for irinotecan-induced dysarthria. 
 
Introduction 
In the US, colorectal cancer is diagnosed in approximately 150,000 patients each 
year. It is the fourth most common form of cancer in the US and the third leading cause 
of cancer-related death in the Western world. In patients with localized disease, 
standard treatment includes surgical resection of the tumor, followed by adjuvant 
chemotherapy in case of regional lymph node metastases. Approximately 50% of 
patients develop distant metastases [1, 2]. Though curative treatment options are 
increasingly available in case of metastatic disease, treatment in this situation is still 
most often palliative. In case of metastatic disease, median overall survival without 
chemotherapy is approximately 8 months, with a 1-year survival of 34%. When 5-
fluorouracil/leucovorin (5-FU/LV) or the equally effective and toxic oral 5-FU prodrug 
capecitabine is combined with irinotecan or oxaliplatin and bevacizumab, the median  
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survival increases to more than 20 months, with a 1-year survival of 74% [2–6]. 
Following first-line treatment with Folfox or Capox, irinotecan is frequently used as 
second-line therapy. Irinotecan (CPT-11) is a prodrug that requires activation by 
carboxylesterases to yield the potent topoisomerase I inhibitor SN-38 that inhibits DNA 
double strand replication and cell division. Well-known side effects of irinotecan are 
the result of the induction of an acute cholinergic syndrome and include rhinitis, 
increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal 
hyperperistalsis. This cholinergic activity is caused by binding of irinotecan to the 
active site gorge of acetylcholinesterase resulting in its subsequent functional 
inhibition [7]. Here, we describe the case of a patient with metastatic rectal carcinoma 
who received second-line therapy with irinotecan and developed isolated transient 
dysarthria following each administration of irinotecan. Although we are aware of the 
reports of 7 patients experiencing this unique and isolated toxic effect, our case is the 
1st to include online supplementary video and speech recordings 
(www.karger.com/doi/10.1159/000336156) [8–13]. 
Case Report 
A 46-year-old male was referred to our outpatient clinic because of metastatic rectal cancer. One 
year earlier he was treated with neoadjuvant capecitabine-based chemoradiotherapy and a low 
anterior resection in another hospital. Six months later, he was treated with radiofrequency ablation 
and transarterial chemoembolization because of liver metastases. As this procedure was complicated 
by sepsis, ischemia of the left liver lobe and abscesses, his clinical condition at that time impeded the 
use of adjuvant chemotherapy. Unfortunately, new liver metastases, lymph node metastases, and an 
adrenal metastasis developed over the next months. After referral to our department, first-line 
palliative chemotherapy (3-weekly: i.v. oxaliplatin 130 mg/m2 day 1; oral capecitabine 1,000 mg/m2 
b.i.d. days 1–14) was initiated. Treatment was well tolerated and resulted in a partial response. 
Unfortunately, progressive disease developed after a total of 10 cycles. After a therapy-free interval of 
2 months, second-line chemotherapy with irinotecan (i.v. 3-weekly; 350 mg/m2) was started. 
Standard premedication included atropine (0.25 mg s.c.), dexamethasone (10 mg i.v.) and 
ondansetron (8 mg i.v.). Approximately 45 min after the irinotecan infusion was started, the patient 
developed dysarthria. A neurologist confirmed that the dysarthria, which resolved spontaneously 
within 24 h, was not accompanied by any other neurological symptom apart from the known NCI-CTC 
grade 1 peripheral polyneuropathy that resulted from prior oxaliplatin exposure. MR imaging of the 
brain, including diffusion weighted imaging, did not show any structural or perfusion abnormalities 
(fig. 1). Upon each 3-weekly readministration of irinotecan, the isolated dysarthria recurred and 
resolved spontaneously within several hours (see accompanying suppl. video). As ondansetron and 
dexamethasone had also been used previously in combination with first-line chemotherapy in this 
patient, these agents could not be responsible for the observed dysarthria. A causative role of atropine 
was excluded by administering atropine premedication (0.25 mg s.c.) 2 h prior to the administration 
of irinotecan; dysarthria did not occur after atropine alone, while subsequent administration of 
irinotecan again induced dysarthria. Acoustic analyses (see video and speech recordings) performed 
by an experienced speech therapist and otolaryngologist indicated a reduced capacity in fine-tuning 
of motor functions of the tip of the tongue and a minimal reduction in the power of speech at 
labiodental contact. Also, a reduction in sound coordination was found predominantly for consonants 
generated by the tip of the tongue. For example, notable changes were observed in the cluster /str/ in 
stretch, destroy, and stranger requiring a coordinated activity of the tip of the tongue and in practice 
requiring a rapid relatively large movement of the tongue. The patient experienced the dysarthria as 
only slightly bothersome and, apart from alopecia, he experienced no other toxicity. After an initial 
radiological response, treatment with irinotecan was stopped after 9 cycles because of progressive 
disease (fig. 2). Presently, the patient is successfully being treated with the EGFR inhibitor 
panitumumab.  
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Discussion 
Speech is based on the fast and varied contractions of oral-, pharyngeal-, and 
laryngeal muscles. Dysarthria is caused by a motility disorder of these muscles caused 
by upper motor neuron lesions of the cerebral hemispheres or lower motor neuron 
lesions of the brain stem, but can also result from disruption of the integrated action of 
upper motor neurons, basal ganglia, and cerebellum [14]. Our patient was evaluated 
before and during several episodes of irinotecan-induced dysarthria. No other 
neurological signs or symptoms were noted and radiological evaluation (conventional 
and diffusion-weighted MRI) showed no abnormalities, which is in line with previously 
reported cases. Analyses by an otolaryngologist and speech therapist indicated that the 
dysarthria predominantly affected consonants generated by the tip of the tongue, and 
although the anatomical level of these disturbances cannot be determined with 
certainty, it is believed to originate centrally at the level of the brainstem. 
The exact pathogenesis of irinotecan-induced dysarthria is still unknown, but 
several possible mechanisms have been put forward. Gomez et al. [8] reported a case in 
which tremors and ataxia preceded the development of dysarthria during the third and 
subsequent cycle of an irinotecan-containing chemotherapy regimen and suggested 
that the use of atropine could prevent progression to dysarthria. Notably, however, this 
preventive effect of additionally administered atropine was not observed in our case or 
in the case reported by Hamberg [12]. This difference could be related to differences in 
the dose of irinotecan, which was substantially lower in the case reported by Gomez et 
al. [8] (60 mg/m2 vs. 350 mg/m2). Atropine itself was not responsible for the observed 
toxicity as we found that its sole administration to the patient did not result in 
dysarthria. Because an earlier study demonstrated that the pharmacokinetics of 
irinotecan were not different in patients developing dysarthria, the isolated dysarthria 
cannot be explained by differences in systemic clearance of irinotecan [12]. Irinotecan 
increases cholinergic activity by binding to the active site gorge of acetylcholinesterase 
resulting in its functional inhibition [7]. Because of its innervation of tongue muscles, 
the hypoglossal nerve plays an important role in speech and its overstimulation or 
damage can cause dysarthria. As the density of cholinergic receptors is relatively high 
in brainstem nuclei and the application of cholinergic agents results in a large increase 
in hypoglossal nerve activity compared to e.g. phrenic nerve activity [15, 16], we 
believe that the occurrence of isolated dysarthria in patients treated with irinotecan 
could be related to this apparent intrinsic increased sensitivity of hypoglossal nerve 
activity to cholinergic stimulation. Unfortunately, we could not directly test this 
hypothesis because of progressive disease in our patient. In future cases, the use of 
pharmacological functional MRI or PET scans with N-[11C]-methyl-4-piperidyl acetate 
to measure acetylcholinesterase activity could be helpful in elucidating the 
pathophysiology of irinotecan-induced isolated dysarthria [17, 18]. 
In conclusion, selective irinotecan-induced dysarthria is an unusual and impressive 
entity, which can occur within minutes of irinotecan infusion. It is potentially related to 
a relative cholinergic oversensitivity of neurons in the area of the nucleus of the 
hypoglossal nerve. Though atropine can decrease cholinergic symptoms, it has not been 
conclusively shown to prevent the occurrence of dysarthria. Of note, as symptoms were 
fully reversible in all cases reported to date (in a period differing from 15 min [9] to 
several hours [this case, 12, 13]) and did not increase in severity upon readministration  
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of irinotecan, awareness of this phenomenon is critical in order to prevent unnecessary 
cessation of a potentially effective anticancer chemotherapeutic agent. 
 
 
 
 
 
 
Fig. 1. Normal magnetic resonance imaging (a, b) and diffusion-weighted magnetic resonance imaging 
(c) of the brain during an episode of irinotecan-induced dysarthria. 
 
 
 
Fig. 2. Abdominal CT scans showing liver metastases (arrows) before irinotecan (a), after 6 cycles of 
irinotecan (b), and after 9 cycles of irinotecan (c). 
 
References 
1  Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus 
leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 
2001;19:4097–4106. 
2  Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus 
leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a 
randomized phase III study. J Clin Oncol 2001;19:2282–2292. 
3  Punt CJ: Chemotherapy of patients with colorectal carcinoma. Ned Tijdschr Geneeskd 2005;149:1441–
1447. 
4  Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin 
for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342. 
5  Walko CM, Lindley C: Capecitabine: a review. Clin Ther 2005;27:23–44.  
Case Rep Oncol 2012;5:47–51 
DOI: 10.1159/000336156 
Published online: 
January 18, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
51 
6  Cassidy J, Clarke S, Díaz-Rubio E, et al: Randomized phase III study of capecitabine plus oxaliplatin 
compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal 
cancer. J Clin Oncol 2008;26:2006–2012. 
7  Harel M, Hyatt JL, Brumshtein B, et al: The crystal structure of the complex of the anticancer prodrug 7-
ethyl-10-[4-(1-piperidino)-1piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica 
acetylcholinesterase provides a molecular explanation for its cholinergic action. Mol Pharmacol 
2005;67:1874–1881. 
8  Gomez JA, Sanchez I, Ramirez JA: Irinotecan-induced dysthria: an insight into its pathognesis? 
Gastrointestinal Cancer Res 2008;2:209–210. 
9  De Marco S, Squilloni E, Vigna L, et al: Irinotecan chemotherapy associated with transient dysarthria and 
aphasis. Ann Oncol 2004;15:1147–1148. 
10  Baz DV, Bofill JS, Nogueira JA: Irinotecan-induced dysarthria. J Natl Cancer Inst 2001;93:1419–1420. 
11  Hamberg P, Donders RC, Ten Bokkel Huinink D: Central nervous system toxicity induced by irinotecan. J 
Natl Cancer Inst 2006;98:219. 
12  Hamberg P, Jong de FA, Brandsma D, et al: Irinotecan-induced central nervous system toxicity. Report on 
two cases and review of literature. Acta Oncol 2008;47:974–978. 
13  Sevilla Garcia I, Rueda A, Alba E: Irinotecan-induced central nervous system toxicity: a case report. J Natl 
Cancer Inst 1999;91:647. 
14  Love RJ, Webb WG: Neurology for the speech-pathologist, 4th edn, Boston, MA, Butterworth-Heinemann, 
2001. 
15  Cortes R, Probst A, Palacios JM: Quantitative light microscopic autoradiographic localization of 
cholinergic muscarinic receptors in the human brain: brainstem. Neuroscience 1984;12:1003–1026. 
16  Haxhiu MA, Mitra J, van Lunteren E, et al: Hypoglossal and phrenic responses to cholinergic agents 
applied to ventral medullary surface. Am J Physiol Regulatory Integrative Comp Physiol 1984;247:939–
944. 
17  Goekoop R, Scheltens P, Barkhof F, et al: Cholinergic challenge in Alzheimer patients and mild cognitive 
impairment differentially affects hippocampal activation – a pharmacological fMRI study. Brain 
2006;129:141–157. 
18  Shimada H, Hirano S, Shinotoh H, et al: Mapping of brain acetylcholinesterase alterations in Lewy body 
disease by PET. Neurology 2009;73:273–278. 